Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis

What Was Tested

Researchers studied Abaloparatide in the context of osteoporosis and bone density in this randomized controlled trial publication.

See Instructions for Authors for a complete description of levels of evidence.

Who Took Part

The study group was 500 women.

PubMed indexes the participants as middle-aged adults and older adults, women only.

This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or placebo (250 patients).

Hip DXA scans underwent 3-dimensional (3D) modeling via 3D-Shaper, followed by virtual resection of the proximal femur and simulated placement of a tapered, flat-wedge hip stem that guided delineation of the Gruen zones that were fully (zones 1 and 7) or largely (zones 2 and 6) captured in the scanning region.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.

Integral, cortical, and trabecular volumetric BMD, cortical thickness, and cortical surface BMD (the product of cortical volumetric BMD and cortical thickness) were determined for each zone.

What Was Measured

See Instructions for Authors for a complete description of levels of evidence.

PubMed files the paper under topics including Parathyroid Hormone-Related Protein, Bone Density, Bone Density Conservation Agents, Absorptiometry, Photon, Osteoporosis, Postmenopausal, Arthroplasty, Replacement, Hip and Femur.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Abaloparatide in 500 women in people with osteoporosis and bone density.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (The Journal of bone and joint surgery. American volume), a journal based in United States.

More context: the Abaloparatide compound page, Osteoporosis and bone density research.